Unlicensed use of metformin in children and adolescents in the UK
Unlicensed use of metformin in children and adolescents in the UK
复制标题
DOI：
10.1111/j.1365-2125.2011.04063.x
复制
发表时间：
2012-01-01
影响因子：
3.4
通讯作者：
Wong, Ian C. K.
中科院分区：
文献类型：
--
作者：
Hsia, Yingfen;Dawoud, Dalia;Wong, Ian C. K.
AIM二甲双胍是年轻人最常开的口服抗糖尿病药物。它还被开出用于治疗多囊卵巢综合征(PCOS)和成人肥胖的未经许可的方式。关于二甲双胍在年轻人中的使用程度，人们知之甚少。我们调查了英国018岁儿童和青少年中二甲双胍的使用情况。方法从2000年1月至2010年12月从英国IMS疾病分析器获得基于人口统计的处方数据。结果2000年至2010年期间，337名患者(80%女性)共开出2674张二甲双胍处方。二甲双胍处方使用率从每千人年0.03例[95%可信区间0.02，0.05]上升到每千人年0.16例(95%可信区间0.12，0.20)(P=0.001)。在16-18岁的女孩中，二甲双胍处方的使用量稳步增加。有290名接受二甲双胍治疗的患者(81%为女性；n=235)至少有一种糖尿病、多囊卵巢综合征或肥胖症的诊断。在这些患者中，PCOS是女孩开二甲双胍最常见的适应症(n=120)，其次是糖尿病。有22例患者(7.6%)仅接受二甲双胍治疗肥胖。结论在2000年至2010年期间，二甲双胍的比例有所上升，尤其是在16-18岁的女孩中。二甲双胍处方的主要适应症是多囊卵巢综合征。目前，二甲双胍没有被批准用于成人或儿童的多囊卵巢综合征和肥胖治疗。由于在年轻人中使用二甲双胍的处方稳步增加，需要进一步的研究来调查这些处方的有效性和安全性。
AIMMetformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 018 years in the UK.METHODSPopulation-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010.RESULTSA total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P = 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n = 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n = 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only.CONCLUSIONSPrescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.